4-氯-6-氟喹唑啉 | 16499-61-9

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 4-氯-6-氟喹唑啉
• 中文别名: 6-氟-4-氯喹唑啉
• 英文名称: 4-chloro-6-fluoroquinazoline
• CAS: 16499-61-9
• 化学式: C₈H₄ClFN₂
• mdl: MFCD07776652
• 分子量: 182.585
• InChiKey: XIKGISGZFBCGDW-UHFFFAOYSA-N

物化性质

• 沸点：
  284.9±20.0 °C(Predicted)
• 密度：
  1.447±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 危险类别码：
  R22,R37/38,R41
• 海关编码：
  2933990090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Chloro-6-fluoroquinazoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Chloro-6-fluoroquinazoline
CAS number: 16499-61-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H4ClFN2
Molecular weight: 182.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-6-氟喹唑啉 在 三乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 31.0h， 生成 1-(5-{2-[(6-fluoroquinazolin-4-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-phenyl-urea
  参考文献：
  名称：

  药物性质优化：口服生物利用喹唑啉基多靶点激酶抑制剂的发现。

  摘要：

  为了开发新的癌症疗法，我们已经在MOLM-13和MV4-11白血病模型以及大肠和胰腺动物模型中报告了临床候选药物BPR1K871（1）作为有效的抗癌化合物。由于BPR1K871缺乏口服生物利用度，我们继续通过药物样性质优化来寻找口服生物利用度类似物。我们优化了1的理化特性（PCP）以及体外大鼠肝脏微粒体的稳定性，同时监测了HCT-116细胞系中的极光激酶抑制和细胞抗增殖活性。喹唑啉核心1的6位和7位的结构修饰导致34被鉴定为口服生物利用型（F％= 54）多激酶抑制剂，对多种癌细胞系表现出有效的抗增殖活性。

  DOI：

  10.1016/j.bioorg.2020.103689
• 作为产物：
  描述：

  6-氟-4-羟基喹唑啉 在 氯化亚砜 作用下， 反应 5.0h， 生成 4-氯-6-氟喹唑啉
  参考文献：
  名称：

  两个系列的 3-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)quinazolin-4(3H)-ones 和 N-(1-benzylpiperidin-4) 的设计、合成和生物评价-基)喹唑啉-4-胺

  摘要：

  两个系列的 3-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]quinazolin-4(3H)-ones 和 N-(1-benzylpiperidin-4-yl)quinazolin-4 - 胺最初被设计为潜在的乙酰胆碱酯酶抑制剂。生物学评估表明，N-(1-benzylpiperidin-4-yl)quinazolin-4-amines 显着抑制 AChE 活性。特别是，与多奈哌齐相比，发现其中的两种化合物最有效，相对 AChE 抑制百分比为 87%。与 AChE 的对接研究显示多奈哌齐和四种衍生物之间的相互作用相似。N-(1-Benzylpiperidin-4-yl)quinazolin-4-amines 也表现出显着的 DPPH 清除作用。这两个系列的化合物还对三种人类癌细胞系，包括 SW620（人类结肠癌）、PC-3（前列腺癌）、和 NCI-H23（肺癌），其中

  DOI：

  10.1002/cbdv.202000290

文献信息

• 4-Aminoquinazoline Derivatives and Uses Thereof
  申请人：SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

  公开号：US20140235633A1

  公开（公告）日：2014-08-21

  The present invention provides a 4-aminoquinazoline derivative having the chemical structure of the following formula, and the use thereof. It is demonstrated by the pharmacological experiment that, the compound or a salt thereof according to the present invention not only has distinct inhibitory effect on histone deacetylases, but also has stronger differentiation induction and anti-proliferative activities for certain tumor cells. It can be used in the treatment of cancers and diseases related to cell differentiation and proliferation. Excellent efficacy is observed especially for leukemia and a solid tumor. As demonstrated by the animal test, the compound or a salt thereof according to the present invention is less toxic.

  本发明提供了一种具有以下化学结构的4-氨基喹唑啉衍生物，以及其用途。药理实验证明，根据本发明的化合物或其盐不仅对组蛋白去乙酰化酶具有明显的抑制作用，而且对某些肿瘤细胞具有更强的分化诱导和抗增殖活性。它可用于治疗与细胞分化和增殖相关的癌症和疾病。特别是对白血病和实体肿瘤观察到了出色的疗效。药物实验证明，根据本发明的化合物或其盐毒性较小。
• AMINO ACID COMPOUNDS AND METHODS OF USE
  申请人：Pliant Therapeutics, Inc.

  公开号：US20200109141A1

  公开（公告）日：2020-04-09

  The invention relates to compounds of formula (I): or a salt thereof, wherein R 1 , G, L 1 , L 2 , L 3 , and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, αvβ 1 integrin and αvβ 6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

  本发明涉及如下公式(I)的化合物： 或其盐，其中R1、G、L1、L2、L3和Y如本文所述。公式(I)的化合物及其药物组合物是αvβ1整合素和/或αvβ6整合素的一种或两种的抑制剂，用于治疗纤维化，如非酒精性脂肪肝炎（NASH）、特发性肺纤维化（IPF）和非特异性间质性肺炎（NSIP）。
• Cyclic derivatives as modulators of chemokine receptor activity
  申请人：Carter H. Percy

  公开号：US20050054627A1

  公开（公告）日：2005-03-10

  The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.

  当前申请描述了MCP-1的调节剂，其化学公式为(I):或其药用可接受的盐形式，用于治疗类风湿性关节炎、多发性硬化症、动脉粥样硬化和哮喘。
• Photochemical intermolecular dearomative cycloaddition of bicyclic azaarenes with alkenes
  作者：Jiajia Ma、Shuming Chen、Peter Bellotti、Renyu Guo、Felix Schäfer、Arne Heusler、Xiaolong Zhang、Constantin Daniliuc、M. Kevin Brown、Kendall N. Houk、Frank Glorius

  DOI：10.1126/science.abg0720

  日期：2021.3.26

  highly regio- and diastereoselective intermolecular [4 + 2] dearomative cycloaddition reaction of these bicyclic azaarenes with a plethora of electronically diverse alkenes. This approach bypasses the general reactivity and selectivity issues, thereby providing various bridged polycycles that previously have been inaccessible or required elaborate synthetic efforts. Computational studies with density

  脱芳环加成反应是将平面芳烃转化为三维结构的理想方法，这在药物化学中日益受到关注。喹啉、异喹啉和喹唑啉尽管含有潜在的二烯和烯烃亚基，但由于芳族体系固有的低反应性和选择性挑战，很少应用于环加成反应。在这里，我们公开了这些双环氮杂芳烃与大量电子不同的烯烃的能量转移介导的、高度区域和非对映选择性的分子间[4 + 2]脱芳香环加成反应。这种方法绕过了一般的反应性和选择性问题，从而提供了以前无法获得或需要精心合成的各种桥连多环。密度泛函理论的计算研究阐明了观察到的区域选择性和非对映选择性的机制和起源。
• ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS
  申请人：Baindur Nand

  公开号：US20060281772A1

  公开（公告）日：2006-12-14

  The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R 1 , R 2 , R 3 , B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  该发明涉及Formula I的烷基喹啉和烷基喹噁啉化合物： 其中R1、R2、R3、B、Z、G、Q和X如本文所定义，所述化合物的用途为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，所述化合物的用途为在细胞或受试者中减少或抑制FLT3和/或c-kit和/或TrkB的激酶活性，以及所述化合物的用途为预防或治疗受试者的细胞增殖紊乱和/或与FLT3和/或c-kit和/或TrkB相关的紊乱。本发明还涉及包括本发明化合物的药物组合物，以及治疗癌症和其他细胞增殖紊乱等疾病的方法。